bluuebunny/crossref_metadata_2025_split huggingface dataset:
From plan to delivery: Machine learning based positional accuracy prediction of multi‐leaf collimator and estimation of delivery effect in volumetric modulated arc therapy
Authors: Qiu Minmin , Zhong Jiajian , Xiao Zhenhua , Deng Yongjin 
Published: June 2024

AbstractPurposeThe positional accuracy of MLC is an important element in establishing the exact dosimetry in VMAT. We comprehensively analyzed factors that may affect MLC positional accuracy in VMAT, and constructed a model to predict MLC positional deviation and estimate planning delivery quality according to the VMAT plans before delivery.MethodsA total of 744 “dynalog” files for 23 VMAT plans were extracted randomly from treatment database. Multi‐correlation was used to analyzed the potential influences on MLC positional accuracy, including the spatial characteristics and temporal variability of VMAT fluence, and the mechanical wear parameters of MLC. We developed a model to forecast the accuracy of MLC moving position utilizing the random forest (RF) ensemble learning method. Spearman correlation was used to further investigate the associations between MLC positional deviation and dosage deviations as well as gamma passing rates.ResultsThe MLC positional deviation and effective impact factors show a strong multi‐correlation (R = 0.701, p‐value < 0.05). This leads to the development of a highly accurate prediction model with average variables explained of 95.03% and average MSE of 0.059 in the 5‐fold cross‐validation, and MSE of 0.074 for the test data was obtained. The absolute dose deviations caused by MLC positional deviation ranging from 12.948 to 210.235 cGy, while the relative volume deviation remained small at 0.470%–5.161%. The average MLC positional deviation correlated substantially with gamma passing rates (with correlation coefficient of −0.506 to −0.720 and p‐value < 0.05) but marginally with dosage deviations (with correlation coefficient < 0.498 and p‐value > 0.05).ConclusionsThe RF predictive model provides a prior tool for VMAT quality assurance.
Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review
Authors: Zhu Yan , Lai Yaoshui , Song Hongjie 
Published: June 2024

AbstractThe patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post‐hepatitis B cirrhosis during the period of compensated liver function. Following a 7‐month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha‐fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.
Expert consensus on quality control indicators of integrative medicine in primary Sjögren's syndrome (2023 version)
Authors: Tao Qing‐Wen , Luo Jing , Wu Tzu‐Hua , Wang Jian‐Ming , Xu Yuan , Jin Di‐Er 
Published: June 2024

AbstractTreatment integrating traditional Chinese and Western medicine for primary Sjögren's syndrome (pSS) has yielded positive results and gained wide acceptance. However, the absence of standardized clinical management in certain regions has led to suboptimal outcomes in the diagnosis and treatment of pSS in China. In response, the Center for Traditional Chinese and Western Medicine at the China‐Japan Friendship Hospital, in collaboration with the Beijing Association of Traditional Chinese and Western Medicine Rheumatology Professional Committee, initiated a project led by the Traditional Chinese Medicine Department of Rheumatism. The project (Beijing Association of the Integrating of Traditional and Western Medicine standardization expert consensus record number: 2021Z031A3) aims to develop a set of quality control indicators for the integrated treatment of pSS using traditional Chinese and Western medicine. Based on the 2021 version, the consensus revision incorporates seven new items, focusing on essential assessment areas for pSS patients, treatment response, and healthcare cost management. The 2023 expert consensus update seeks to enhance pSS diagnosis and treatment practices in China, offering a benchmark for medical quality control.
Antimicrobial Peptide Coating of TiO2 Nanoparticles for Boosted Antimicrobial Effects
Authors: Caselli Lucrezia , Traini Tanja , Micciulla Samantha , Sebastiani Federica , Köhler Sebastian , Nielsen Emilie Marie , Diedrichsen Ragna Guldsmed , Skoda Maximilian W. A. , Malmsten Martin 
Published: June 2024

AbstractThis study explores the coating of photocatalytic nanoparticles with antimicrobial peptides (AMPs) for boosted antimicrobial effects, and how such effects depend on AMP properties. For this, TiO2 nanoparticles are coated with the AMP KYE21 or its hydrophobically enhanced variant WWWKYE21. Mirroring effects of free peptides, coated nanoparticles displayed higher binding and UV‐induced degradation for bacteria‐like than for mammalian‐like membranes. In addition, they degraded bacterial lipopolysaccharides (LPS). WWWKYE21‐coated nanoparticles displayed higher binding to LPS and bacteria‐like membranes and photocatalytic degradation, although saturation effects are found at high nanoparticle binding. Neutron reflectometry showed that binding of peptide‐coated nanoparticles to bacteria‐like membranes resulted in partial lipid removal in the absence of UV, but that UV illumination caused additional degradation, featuring increases in the hydration of headgroup and acyl chain regions. For LPS, UV induced removal of its outer O‐antigen region. Analogous to findings in model systems, antimicrobial effects of peptide‐coated nanoparticles against Escherichia coli bacteria on illumination are pronounced, while toxicity against human monocytes remained low. Altogether, results show that AMP coating boosts the antimicrobial effects of photocatalytic nanoparticles without causing cell toxicity. From a broader perspective, the study points to the potential of nanoarchitectonic combination of component properties for the design of composite NP properties.
Rapid and Precise Molecular Nanofiltration Using Ultra‐Thin‐Film Membranes Derived from 6,6′‐Dihydroxy‐2,2′‐biphenyldiamine
Authors: Chen Youcai , Shi Wenxiong , Li Shao‐Lu , Wang Mengfan , Wang Jian , Hao Shuang , Gong Genghao , Ye Chunchun , McKeown Neil B. , Hu Yunxia 
Published: June 2024

AbstractA key challenge in efficient molecular separation is fabricating large‐scale, highly selective polymeric membranes with precise pore control at the molecular scale. Herein, a new contorted monomer 6,6′‐dihydroxy‐2,2′‐biphenyldiamine (DHBIPDA) is introduced as a building block to generate cross‐linked, ultra‐thin microporous nanofilms (sub‐10 nm) via interfacial polymerization, enabling rapid, and precise molecular nanofiltration. Using diacyl chloride (TPC) as the cross‐linker instead of trimesoyl chloride (TMC) significantly reduces the pore sizes within the membranes and achieves a narrower pore distribution due to a semi‐crystalline structure. The film structures are confirmed using comprehensive characterization techniques including wide‐angle X‐ray scattering (WAXS), X‐ray diffraction (XRD), positron annihilation lifetime spectroscopy (PALS), CO2 adsorption analysis, and molecular‐scale simulation. The DHBIPDA/TPC and DHBIPDA/TMC membranes achieve methanol permeance values of up to 16.4 and 15.1 LMH bar−1 coupled with molecular weight cutoffs (MWCOs) as low as 283 and 306 Da, respectively. The DHBIPDA/TPC membrane demonstrates both higher permeance and higher selectivity compared to its relatively disordered counterpart DHBIPDA/TMC, consistent with characterization data. The DHBIPDA‐derived membrane efficiently separates dye mixtures with similar molecular weights and enables effective recycling of organometallic homogeneous catalysts, suggesting its potential for industrial applications.
An Acellular, Self‐Healed Trilayer Cryogel for Osteochondral Regeneration in Rabbits
Authors: Chen Tsai‐Yu , Dai Niann‐Tzyy , Wen Tsung‐Kai , Hsu Shan‐hui 
Published: June 2024

AbstractOsteochondral regeneration remains formidable challenges despite significant advances in microsurgery. Herein, an acellular trilayer cryogel (TC) with injectability, tunable pore sizes (80–200 µm), and appropriate compressive modulus (10.8 kPa) is manufactured from self‐healable hydrogel under different gelling times through Schiff reaction between chitosan and difunctionalized polyurethane (DFPU). Bioactive molecules (Y27632 and dexamethasone) are respectively loaded in the top and bottom layers to form the Y27632/dexamethasone‐loaded trilayer cryogel (Y/DEX‐TC). Mesenchymal stem cells (MSCs) seeded in Y/DEX‐TC proliferated ≈350% in vitro and underwent chondrogenesis or osteogenesis in response to the respective release of Y or DEX in 14 days. Acupuncture is administered to animals in an attempt to modulate the innate regulatory system and mobilize endogenous MSCs for osteochondral defect regeneration. In vivo rabbit experiments using Y/DEX‐TC combined with acupuncture successfully regulate SDF‐1 and TGF‐β1 levels, which possibly cause MSC migration toward Y/DEX‐TC. The synergistic effect of cryogel and acupuncture on immunomodulation is verified with a ≈7.3‐fold enhancement of the M2‐/M1‐macrophage population ratio by treatment of Y/DEX‐TC combining acupuncture, significantly greater than ≈1.5‐fold increase by acupuncture or ≈2.2‐fold increase by Y/DEX‐TC alone. This novel strategy using acellular drug‐loaded cryogel and accessible acupuncture shows promise in treating osteochondral defects of joint damage.
Bias‐Free Cardiac Monitoring Capsule
Authors: Qu Xuecheng , Cheng Sijing , Liu Ying , Hu Yiran , Shan Yizhu , Luo Ruizeng , Weng Sixian , Li Hui , Niu Hongxia , Gu Min , Fan Yubo , Shi Bojing , Liu Zhuo , Hua Wei , Li Zhou , Wang Zhong Lin 
Published: June 2024

AbstractCardiovascular disease (CVD) remains the leading cause of death worldwide. Patients often fail to recognize the early signs of CVDs, which display irregularities in cardiac contractility and may ultimately lead to heart failure. Therefore, continuously monitoring the abnormal changes in cardiac contractility may represent a novel approach to long‐term CVD surveillance. Here, a zero‐power consumption and implantable bias‐free cardiac monitoring capsule (BCMC) is introduced based on the triboelectric effect for cardiac contractility monitoring in situ. The output performance of BCMC is improved over 10 times with nanoparticle self‐adsorption method. This device can be implanted into the right ventricle of swine using catheter intervention to detect the change of cardiac contractility and the corresponding CVDs. The physiological signals can be wirelessly transmitted to a mobile terminal for analysis through the acquisition and transmission module. This work contributes to a new option for precise monitoring and early diagnosis of CVDs.
Isomerization Engineering of Solid Additives Enables Highly Efficient Organic Solar Cells via Manipulating Molecular Stacking and Aggregation of Active Layer
Authors: Miao Yawei , Sun Yanna , Zou Wentao , Zhang Xu , Kan Yuanyuan , Zhang Wenqing , Jiang Xinyue , Wang Xunchang , Yang Renqiang , Hao Xiaotao , Geng Longlong , Xu Huajun , Gao Ke 
Published: June 2024

AbstractMorphology control is crucial in achieving high‐performance organic solar cells (OSCs) and remains a major challenge in the field of OSC. Solid additive is an effective strategy to fine‐tune morphology, however, the mechanism underlying isomeric solid additives on blend morphology and OSC performance is still vague and urgently requires further investigation. Herein, two solid additives based on pyridazine or pyrimidine as core units, M1 and M2, are designed and synthesized to explore working mechanism of the isomeric solid additives in OSCs. The smaller steric hindrance and larger dipole moment facilitate better π–π stacking and aggregation in M1‐based active layer. The M1‐treated all‐small‐molecule OSCs (ASM OSCs) obtain an impressive efficiency of 17.57%, ranking among the highest values for binary ASM OSCs, with 16.70% for M2‐treated counterparts. Moreover, it is imperative to investigate whether the isomerization engineering of solid additives works in state‐of‐the‐art polymer OSCs. M1‐treated D18‐Cl:PM6:L8‐BO‐based devices achieve an exceptional efficiency of 19.70% (certified as 19.34%), among the highest values for OSCs. The work provides deep insights into the design of solid additives and clarifies the potential working mechanism for optimizing the morphology and device performance through isomerization engineering of solid additives.
An Ultralight Composite Current Collector Enabling High‐Energy‐Density and High‐Rate Anode‐Free Lithium Metal Battery
Authors: Ouyang Zhaofeng , Wang Shuo , Wang Yan , Muqaddas Sheza , Geng Shitao , Yao Zhibo , Zhang Xiao , Yuan Bin , Zhao Xiaoju , Xu Qiuchen , Tang Shanshan , Zhang Qiang , Li Jun , Sun Hao 
Published: June 2024

AbstractAnode‐free lithium (Li) metal batteries are promising alternatives to current Li‐ion batteries due to their advantages such as high energy density, low cost, and convenient production. However, the copper (Cu) current collector accounts for more than 25 wt% of the total weight of the anode‐free battery without capacity contribution, which severely reduces the energy and power densities. Here, a new family of ultralight composite current collectors with a low areal density of 0.78 mg cm−2, representing significant weight reduction of 49%‐91% compared with the Cu‐based current collectors for high‐energy Li batteries, is presented. Rational molecular engineering of the polyacylsemicarbazide substrate enables enhanced interfacial interaction with the sputtered Cu layer, which results in excellent interfacial stability, flexibility, and safety for the obtained anode‐free batteries. The battery‐level energy density has been significantly improved by 36%–61%, and a maximum rate capability reaches 5 C (10 mA cm−2) attributed to the homogeneous Li+ flux and smooth Li deposition on the nanostructured Cu layer. The results not only open a new avenue to improve the energy and power densities of anode‐free batteries via composite current collector innovation but, in a broader context, provide a new paradigm to pursue high‐performance, high‐safety, and flexible batteries.
Systematic Exploration of the Benefits of Ni Substitution in Na–Fe–Mn–O Cathodes
Authors: Abdolhosseini Marzieh , Jia Shipeng , Sieffert Michael , Eisnor Maddison , Kumakura Shinichi , McCalla Eric 
Published: June 2024

AbstractNa‐ion batteries (SIBs) are receiving a great deal of attention as potential sustainable replacements for Li‐ion batteries in electric vehicles and grid storage applications. To date, commercialized SIBs offer inferior energy density with passable extended cycling. By contrast, next‐generation SIBs will likely utilize layered oxide cathodes that offer improved energy density but to date show inferior stability both during cycling and in terms of stability of the cathodes in air during cell assembly. These properties are highly tunable with composition and herein the promising P2 phases are systematically explored in the Na–Fe–Mn–O phase diagram by making 256 different compositions. The optimal material is a P2 material saturated with Ni (a modest 16% of the transition metal layer) and shows a highly competitive energy density of 640 Wh kg−1 while minimizing the amount of sacrificial sodium needed in full cells and also improving the air stability of the material. This study shows the vital role that thorough systematic screening will play in the continued development of these vital materials for sustainable secondary battery production and provides guidance toward sustainable Na‐ion cathodes by minimizing the nickel content required for high performance.
Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer
Authors: Song Weiguo , Yang Hekai , Wang Ying , Chen Shuzhen , Zhong Wenda , Wang Qian , Ding Wenshuo , Xu Guangzhao , Meng Chen , Liang Ying , Chen Zhe‐Sheng , Cao Shuhua , Wei Liuya , Li Fahui 
Published: June 2024

AbstractMulti‐drug resistance (MDR) is a major cause of cancer therapy failure. Photodynamic therapy (PDT) is a promising modality that can circumvent MDR and synergize with chemotherapies, based on the generation of reactive oxygen species (ROS) by photosensitizers. However, overproduction of glutathione (GSH) by cancer cells scavenges ROS and restricts the efficacy of PDT. Additionally, side effects on normal tissues are unavoidable after PDT treatment. Here, to develop organic systems that deliver effective anticancer PDT and chemotherapy simultaneously with very little side effects, three GSH‐sensitive photosensitizer‐drug conjugates (CyR‐SS‐L) are designed and synthesized. CyR‐SS‐L localized in the mitochondria then is cleaved into CyR‐SG and SG‐L parts by reacting with and consuming high levels of intracellular GSH. Notably, CyR‐SG generates high levels of ROS in tumor cells instead of normal cells and be exploited for PDT and the SG‐L part is used for chemotherapy. CyR‐SS‐L inhibits better MDR cancer tumor inhibitory activity than indocyanine green, a photosensitizer (PS) used for PDT in clinical applications. The results appear to be the first to show that CyR‐SS‐L may be used as an alternative PDT agent to be more effective against MDR cancers without obvious damaging normal cells by the combination of PDT, GSH depletion, and chemotherapy.
A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy
Authors: Chen Yingzhi , Li Ruike , Duan Qiao , Wu Lingling , Li Xinyi , Luo Aoxiang , Zhang Yongming , Zhao Na , Cui Kai , Wu Wenwei , Liu Tize , Wan Jian‐Bo , Deng Liufu , Li Guiying , Hou Lijun , Tan Weihong , Xiao Zeyu 
Published: June 2024

AbstractThe activation of cyclic GMP‐AMP (cGAMP) synthase (cGAS) and its adaptor, stimulator of interferon genes (STING), is known to reprogram the immunosuppressive tumor microenvironment for promoting antitumor immunity. To enhance the efficiency of cGAS‐STING pathway activation, macrophage‐selective uptake, and programmable cytosolic release are crucial for the delivery of STING agonists. However, existing polymer‐ or lipid‐based delivery systems encounter difficulty in integrating multiple functions meanwhile maintaining precise control and simple procedures. Herein, inspired by cGAS being a natural DNA sensor, a modularized DNA nanodevice agonist (DNDA) is designed that enable macrophage‐selective uptake and programmable activation of the cGAS‐STING pathway through precise self‐assembly. The resulting DNA nanodevice acts as both a nanocarrier and agonist. Upon local administration, it demonstrates the ability of macrophage‐selective uptake, endosomal escape, and cytosolic release of the cGAS‐recognizing DNA segment, leading to robust activation of the cGAS‐STING pathway and enhanced antitumor efficacy. Moreover, DNDA elicits a synergistic therapeutic effect when combined with immune checkpoint blockade. The study broadens the application of DNA nanotechnology as an immune stimulator for cGAS‐STING activation.
Quantum‐Dot‐Induced Energy Filtering Effect in Organic Thermoelectric Nanocomposites
Authors: Kim Daegun , Kim Jimin , Chung Sein , Cho Kilwon 
Published: June 2024

AbstractThermoelectric (TE) charge transport in organic TE nanocomposite systems is a critical consideration in designing high‐performance TE materials. Here, the relationship between the TE properties and energy structure of conducting polymer/quantum dot (QD) nanocomposites is systematically investigated by developing a potential wall or potential well in poly(3,4‐ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS) with CdTe QDs. The added QDs are primarily distributed within the electrically insulating PSS shell and act as stepping stones for charge transport between PEDOT‐rich grains. The embedded QDs generate an energy‐filtering effect, which is induced by both potential wall and potential well states established by the QDs in the PEDOT:PSS films. The induced energy‐filtering effect increases the Seebeck coefficient S with limited loss of electrical conductivity σ, thereby overcoming the TE trade‐off relation S ∝ σ
−1/4. The energy‐filtering effect is optimized by carefully controlling the QD size. The PEDOT:PSS/QD nanocomposite containing the smallest QDs exhibits a power factor of 173.8 µW m−1 K−2, which is 80% larger than the value for the pristine PEDOT:PSS film. This work suggests a strategy for designing TE nanocomposites with improved TE performance and emphasizes the importance of fine‐tuning the interfacial energy gap to achieve an effective energy‐filtering effect.
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Authors: Garciaz Sylvain , Dumas Pierre‐Yves , Bertoli Sarah , Sallman David A. , Decroocq Justine , Belhabri Amine , Orvain Corentin , Aspas Requena Gaspar , Simand Celestine , Laribi Kamel , Carré Martin , Santagostino Alberto , Himberlin Chantal , Peterlin Pierre , Bonnet Sarah , Chan Onyee , Lancet Jeffrey , Komrokji Rami , Vergez François , Chapuis Nicolas , Raskovalova Tatiana , Plesa Adriana , Lhoumeau Anne‐Catherine , Mineur Ariane , Hospital Marie Anne , Pigneux Arnaud , Vey Norbert , Récher Christian 
Published: June 2024

AbstractVenetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE‐A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax‐azacitidine due to poor tolerance. Sixty‐two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort (n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow‐up of 23 months (IQR, 20–32), median overall survival and treatment‐free survival were 44 (IQR, 16‐NR) and 16 (IQR, 8–27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2‐year treatment‐free survival of 80%. In the RR cohort (n = 22), median overall survival and treatment‐free survival were 19 (IQR, 17–31) and 10 (IQR, 5‐NR) months, respectively. Prior number of venetoclax‐azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment‐free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials.